Suppr
超能文献

Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance?

作者信息

Binder Susanne

出版信息

Br J Ophthalmol. 2012 Jan;96(1):1-2. doi: 10.1136/bjophthalmol-2011-301236.

DOI:10.1136/bjophthalmol-2011-301236

PMID:22157632

Abstract

摘要

相似文献

Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance?

Br J Ophthalmol. 2012 Jan;96(1):1-2. doi: 10.1136/bjophthalmol-2011-301236.

Resistance, not tachyphylaxis or tolerance.

Br J Ophthalmol. 2012 Aug;96(8):1153-4. doi: 10.1136/bjophthalmol-2012-301823. Epub 2012 Apr 17.

Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation.

Br J Ophthalmol. 2012 Jan;96(1):14-20. doi: 10.1136/bjo.2011.204685. Epub 2011 Jul 26.

Same-day consecutive bilateral intravitreal injections of ranibizumab for the treatment of bilateral active choroidal neovascularization in age-related macular degeneration.

Acta Ophthalmol. 2012 Sep;90(6):e491-3. doi: 10.1111/j.1755-3768.2011.02327.x. Epub 2012 Jan 23.

Bevacizumab and triamcinolone acetonide for choroidal neovascularization due to age-related macular degeneration unresponsive to antivascular endothelial growth factors.

J Ocul Pharmacol Ther. 2013 May;29(4):437-41. doi: 10.1089/jop.2012.0173. Epub 2012 Dec 6.

Comparing ranibizumab with bevacizumab.

Ophthalmology. 2011 Mar;118(3):600-600.e2. doi: 10.1016/j.ophtha.2010.10.027.

Bimonthly injections of ranibizumab for age-related macular degeneration.

Graefes Arch Clin Exp Ophthalmol. 2015 May;253(5):823. doi: 10.1007/s00417-014-2877-y. Epub 2014 Dec 9.

Evaluation of changes in choroidal neovascularization secondary to age-related macular degeneration after anti-VEGF therapy using spectral domain optical coherence tomography.

Curr Eye Res. 2012 May;37(5):438-45. doi: 10.3109/02713683.2011.647227.

Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab.

Br J Ophthalmol. 2012 Jan;96(1):21-3. doi: 10.1136/bjo.2011.203893. Epub 2011 Jul 6.

Endothelial progenitor cells and plasma vascular endothelial growth factor and stromal cell-derived factor-1 during ranibizumab treatment for neovascular age-related macular degeneration.

J Ocul Pharmacol Ther. 2013 Jul-Aug;29(6):530-8. doi: 10.1089/jop.2012.0013. Epub 2013 Apr 10.

引用本文的文献

Aqueous humor cytokine profile in insufficient responder to aflibercept for neovascular age-related macular degeneration.

Int Ophthalmol. 2025 Aug 9;45(1):326. doi: 10.1007/s10792-025-03678-0.

Effect of simultaneous intravitreal ranibizumab and extended-release dexamethasone injection on patients with naïve versus refractory retinal vein occlusion macular edema: a prospective, multicenter, and interventional open-label study.

Int J Ophthalmol. 2025 May 18;18(5):860-867. doi: 10.18240/ijo.2025.05.11. eCollection 2025.

Efficacy of Aflibercept (8 mg) for Diabetic Macular Edema in Vitrectomized Eyes Refractory to the Other Anti-VEGF Drug Therapies: A Report of Three Cases.

Int Med Case Rep J. 2025 Apr 5;18:465-471. doi: 10.2147/IMCRJ.S512953. eCollection 2025.

Peptide Lv and Angiogenesis: A Newly Discovered Angiogenic Peptide.

Biomedicines. 2024 Dec 15;12(12):2851. doi: 10.3390/biomedicines12122851.

Evaluating the Efficacy of Conbercept and Dexamethasone Implants Sequentially in the Treatment of Refractory Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO): A One-Year Follow-Up Study.

Clin Ophthalmol. 2024 Sep 30;18:2721-2730. doi: 10.2147/OPTH.S487248. eCollection 2024.

Switch to faricimab after initial treatment with aflibercept in eyes with neovascular age-related macular degeneration.

Int Ophthalmol. 2024 Sep 5;44(1):369. doi: 10.1007/s10792-024-03297-1.

Switching to the aflibercept (3 mg) therapy for treatment-resistant wet age-related macular degeneration: 1-year outcomes.

Medicine (Baltimore). 2024 Apr 19;103(16):e37839. doi: 10.1097/MD.0000000000037839.

Epigallocatechin-3-Gallate, an Active Green Tea Component to Support Anti-VEGFA Therapy in Wet Age-Related Macular Degeneration.

Nutrients. 2023 Jul 28;15(15):3358. doi: 10.3390/nu15153358.

Pharmacotherapy and Nutritional Supplements for Neovascular Eye Diseases.

Medicina (Kaunas). 2023 Jul 20;59(7):1334. doi: 10.3390/medicina59071334.

Volumetric fluid analysis of fixed monthly anti-VEGF treatment in patients with neovascular age-related macular degeneration.

Int J Ophthalmol. 2023 Jun 18;16(6):909-914. doi: 10.18240/ijo.2023.06.12. eCollection 2023.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Suppr超能文献

Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance?

作者信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译